Olmesartan medoxomil: current status of its use in monotherapy
Hans R BrunnerLausanne University, Lausanne and Medizinische Poliklik, Universitaetsspital, Basel, SwitzerlandAbstract: Olmesartan medoxomil is an angiotensin II receptor antagonist. In pooled analyses of seven randomized, double-blind trials, 8 weeks’ treatment with olmesartan medoxomil w...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2006-12-01
|
Series: | Vascular Health and Risk Management |
Online Access: | https://www.dovepress.com/olmesartan-medoxomil-current-status-of-its-use-in-monotherapy-peer-reviewed-article-VHRM |
id |
doaj-e902ff8ebefb420ea734aaf301a323d7 |
---|---|
record_format |
Article |
spelling |
doaj-e902ff8ebefb420ea734aaf301a323d72020-11-24T20:54:56ZengDove Medical PressVascular Health and Risk Management1178-20482006-12-01Volume 23273401434Olmesartan medoxomil: current status of its use in monotherapyHans R BrunnerHans R BrunnerLausanne University, Lausanne and Medizinische Poliklik, Universitaetsspital, Basel, SwitzerlandAbstract: Olmesartan medoxomil is an angiotensin II receptor antagonist. In pooled analyses of seven randomized, double-blind trials, 8 weeks’ treatment with olmesartan medoxomil was significantly more effective than placebo in terms of the response rate, proportion of patients achieving target blood pressure (BP) and mean change from baseline in diastolic (DBP) and systolic blood pressure (SBP). Olmesartan medoxomil had a fast onset of action, with significant between-group differences evident from 2 weeks onwards. The drug was well tolerated with a similar adverse event profile to placebo. In patients with type 2 diabetes, olmesartan medoxomil reduced renal vascular resistance, increased renal perfusion, and reduced oxidative stress. In several large, randomized, double-blind trials, olmesartan medoxomil 20 mg has been shown to be significantly more effective, in terms of primary endpoints, than recommended doses of losartan, valsartan, irbesartan, or candesartan cilexetil, and to provide better 24 h BP protection. Olmesartan medoxomil was at least as effective as amlodipine, felodipine and atenolol, and significantly more effective than captopril. The efficacy of olmesartan medoxomil in reducing cardiovascular risk beyond BP reduction is currently being investigated in trials involving patients at high risk due to atherosclerosis or type 2 diabetes. Keywords: olmesartan medoxomil, hypertension, angiotensin receptor antagonisthttps://www.dovepress.com/olmesartan-medoxomil-current-status-of-its-use-in-monotherapy-peer-reviewed-article-VHRM |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hans R Brunner |
spellingShingle |
Hans R Brunner Olmesartan medoxomil: current status of its use in monotherapy Vascular Health and Risk Management |
author_facet |
Hans R Brunner |
author_sort |
Hans R Brunner |
title |
Olmesartan medoxomil: current status of its use in monotherapy |
title_short |
Olmesartan medoxomil: current status of its use in monotherapy |
title_full |
Olmesartan medoxomil: current status of its use in monotherapy |
title_fullStr |
Olmesartan medoxomil: current status of its use in monotherapy |
title_full_unstemmed |
Olmesartan medoxomil: current status of its use in monotherapy |
title_sort |
olmesartan medoxomil: current status of its use in monotherapy |
publisher |
Dove Medical Press |
series |
Vascular Health and Risk Management |
issn |
1178-2048 |
publishDate |
2006-12-01 |
description |
Hans R BrunnerLausanne University, Lausanne and Medizinische Poliklik, Universitaetsspital, Basel, SwitzerlandAbstract: Olmesartan medoxomil is an angiotensin II receptor antagonist. In pooled analyses of seven randomized, double-blind trials, 8 weeks’ treatment with olmesartan medoxomil was significantly more effective than placebo in terms of the response rate, proportion of patients achieving target blood pressure (BP) and mean change from baseline in diastolic (DBP) and systolic blood pressure (SBP). Olmesartan medoxomil had a fast onset of action, with significant between-group differences evident from 2 weeks onwards. The drug was well tolerated with a similar adverse event profile to placebo. In patients with type 2 diabetes, olmesartan medoxomil reduced renal vascular resistance, increased renal perfusion, and reduced oxidative stress. In several large, randomized, double-blind trials, olmesartan medoxomil 20 mg has been shown to be significantly more effective, in terms of primary endpoints, than recommended doses of losartan, valsartan, irbesartan, or candesartan cilexetil, and to provide better 24 h BP protection. Olmesartan medoxomil was at least as effective as amlodipine, felodipine and atenolol, and significantly more effective than captopril. The efficacy of olmesartan medoxomil in reducing cardiovascular risk beyond BP reduction is currently being investigated in trials involving patients at high risk due to atherosclerosis or type 2 diabetes. Keywords: olmesartan medoxomil, hypertension, angiotensin receptor antagonist |
url |
https://www.dovepress.com/olmesartan-medoxomil-current-status-of-its-use-in-monotherapy-peer-reviewed-article-VHRM |
work_keys_str_mv |
AT hansrbrunner olmesartanmedoxomilcurrentstatusofitsuseinmonotherapy |
_version_ |
1716793249153155072 |